On Jul 28, 2:25*pm, "Edward Dolan" wrote:
"JimmyMac" wrote in message

...
On Jul 24, 9:55 pm, "Edward Dolan" wrote:
[...]

The cost of organically grown foods at the supermarket is beyond the means
of the average consumer. Only upper middle class types can afford it.
You missed or deliberately ignore my point regarding foods (some

genetically modified) laced with herbicides, pesticides, hormones,
antibiotics contributing to ever increasing health care costs. *What
with insurance premiums, deductibles, co-pays, etc., out of pocket
heath care costs are beyond the means for many of us.

Health care costs are outrageously expensive. The Damn Dems (Obama Care)
never know how to fix anything. America badly needs a single payer system
like they have in Canada and the UK. However, some folks still believe that
health care is NOT a right!

The FDA determines whether foods are safe or not, not food cranks who write
for magazines like Prevention.

This nonsensical assertion should come as no surprise. After all,
this is from the very same uniformed person who asserts that meat is
meat failing to recognize that white meat is different from red, that
free range organically raised livestock is different from livestock
fed genetically modified feed laced with herbicides and pesticides,
that livstock shot injected with hormones and antibiotics are the same
as livestock that is not. There was a time when cattle were injected
with clenbuteriol and were fed newspaper and concrete powder to fatten
them up, but hey meat is meat because dunderhead Dolan says so; and,
as he is quick to point out, facts are irrelevant since Ed is about
opinion. Opinions not based on fact is virtually worthless. Many of
Dolan's opinions are not based on fact. From this one can conclude
that many of Dolan's opinions are worthless.

Ed has this habit of seizing every opportunity to run his mouth and
embarrass himself. Familiarization with the subject matter at hand
has never been a requirement for Ed to render an opinion. Let's have
a look at Ed's beloved FDA shall we?

The FDA sets compliance guidelines limiting the amount of contaminants
in food, but allows a percentage of mold, parasites, rodent hairs,
animal droppings (feces), insect droppings (feces), insect parts,
insect eggs maggots, whole insects, sand and grit, sticks and stones,
and even cigarette butts. A small percent Ed might counter. Well,
think again. A University of Ohio fact study estimates that on
average a person consumes from one to two pounds of insects each year,
without even knowing it.

So much for the FDA and Food, but what about drugs, Ed might say?

Well, Fen Phen, Redux, Seldane, Posicor, Duract, Hismanal, Rezulin,
Propulsid, Lotronex, Raplon, Baycol, and Raxar are the so-called dirty
dozen drugs that the FDA pulled from the market from 1997 to 2001
because they caused a whole bunch of problems, all of which had
lawsuits attached to them. In some cases, these medicines were on the
market for over twenty years, which seems way to long after known
health adverse reactions occurred. Some of these adverse reactions
only took months to get the medicines removed.

The there are thoss drugs that the FDA dragged their feet on causing
many unnecessary premature deaths.

By the time FDA approved Gleevec in March 2003, approximately 3,600
patients had been denied access to the drug. Many died waiting. More
than 80% of the small number of patients who got Gleevec in clinical
trials before the drug was approved are alive today.

Eloxatin, for advanced colorectal cancer, was summarily rejected by
the FDA in March 2000 despite its being approved in at least 29 other
countries. The FDA delayed approval until August. In between, about
40,000 Americans died without ever getting the drug.

Erbitux, for the treatment of colorectal and head and neck cancers,
was rejected by FDA n December 2001. The FDA delayed approval until
February 2004. Almost 179,000 people with colorectal and head and neck
cancer died waiting.

Patients had to wait until December 2005 for FDA approval. Nearly
74,000 patients with these terminal cancers died without ever getting
Revlimid.

in June 2004, we started pushing the FDA to make Nexavar and Sutent,
both highly promising drugs for kidney cancer, available. The agency
eventually approved Nexavar in December 2005 and Sutent in January
2006. But that was only after evidence of efficacy so compelling
emerged for Nexavar that the trial demanded by the FDA -- in which
dying kidney cancer patients seeking the drug were being given no
other choice (except certain death from their cancer) but to agree to
a 50/50 chance of being blindly randomized to a sugar pill -- was
stopped by Bayer for ethical reasons and the placebo patients allowed
to get the drug. The sponsor seeking approval for Sutent was given a
similar option by FDA if it wanted its drug approved. About 20,000
kidney cancer patients died waiting for both drugs.

After a three year delay,, the FDA approved the drug in November 2004.
In the interim, 531,000 people with lung cancer died. Tarceva also
extends the effectiveness of an existing drug for pancreatic cancer,
and about 102,000 patients died from that disease during the FDA's
delay.

FDA a two year delay, the FDAfinally approved this obviously effective
cancer drug in February 2004. It is now approved for colorectal and
lung cancers, and being successfully used off label for several more.
Almost 360,000 patients with lung and colon cancer died without ever
getting Avastin.

After a two year delay,the FDA approved Alimta for lung cancer
patients. n the interim, approximately 249,000 lung cancer patients
died without the chance of trying this drug to see if it would control
their disease or extend their life.

After a two year delay, the FDA approved Tykerb for breast cancer.
About 25% of breast cancers include the biomarker predictive of
benefit from Tykerb; nearly 28,000 women who had this marker died from
their cancer waiting for Tykerb. They would, according to the FDA,
have each lived an average of eight months longer.

The American Cancer Society reports that some 550,000 cancer patients
die annually, making the number of cancer deaths from 1997 to 2005
about 4.8 million. Over that same period, the FDA reports granting
individual access to an investigational drug to not more than 650
people per year for all diseases and drugs -- a pathetic, even cruel,
pittance. A few thousand more patients managed to gain access by
enrolling in relatively small clinical trials.

Unlike Ed, I don't state opinions as though they were facts. Unlike
Ed, I corroborate my statements. When I argue, I cite facts and I
have cited enough facts above to indicate that Ed's faith in the FDA
is questionable.

Ed Dolan the Great - Minnesota
aka
Saint Edward the Great - Order of the Perpetual Sorrows - Minnesota